To make it clearer, our team put together a quick comparison
We expect between 15 and 20 percent to discontinue the medication within the first year. Q: Knowing that, what is Wellmarks stance on GLP-1s
Western Pennsylvania Townhall 2025 presentation Follow-up Q&A International Drug Sourcing (Blue Cross Blue Shield) International Drug Sourcing (Blue Shield) Questions
Among 331,863 matched GLP-1RAs users, the hazard ratios for pneumonia and severe sepsis were 0.60 (95% CI, 0.580.62) and 0.61 (95% CI, 0.590.63), respectively, indicating a substantial risk reduction relative to the DPP-1 is cohort ( , IL-1, IL-6, CXCL1), suppression of neutrophil infiltration, and decreased expression of genes associated with tissue remodeling and inflammation (Mmp9, Timp1, Ly6g)
The actual results exceeded expectations
Efficacy comparison by clinical trial data The most relevant head-to-head data comes from the SURPASS-2 trial (tirzepatide vs semaglutide 1 mg for type 2 diabetes) and the SURMOUNT-5 trial (tirzepatide vs semaglutide 2.4 mg for obesity)